GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » Equity-to-Asset

Ascendis Pharma AS (STU:A71) Equity-to-Asset : -0.09 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma AS Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ascendis Pharma AS's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €-105.7 Mil. Ascendis Pharma AS's Total Assets for the quarter that ended in Dec. 2024 was €1,179.5 Mil. Therefore, Ascendis Pharma AS's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was -0.09.

The historical rank and industry rank for Ascendis Pharma AS's Equity-to-Asset or its related term are showing as below:

STU:A71' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18   Med: 0.87   Max: 0.93
Current: -0.09

During the past 13 years, the highest Equity to Asset Ratio of Ascendis Pharma AS was 0.93. The lowest was -0.18. And the median was 0.87.

STU:A71's Equity-to-Asset is ranked worse than
87.18% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs STU:A71: -0.09

Ascendis Pharma AS Equity-to-Asset Historical Data

The historical data trend for Ascendis Pharma AS's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Equity-to-Asset Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.81 0.24 -0.18 -0.09

Ascendis Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.30 -0.42 -0.09 -0.09

Competitive Comparison of Ascendis Pharma AS's Equity-to-Asset

For the Biotechnology subindustry, Ascendis Pharma AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Equity-to-Asset falls into.


;
;

Ascendis Pharma AS Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ascendis Pharma AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-105.706/1179.495
=-0.09

Ascendis Pharma AS's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-105.706/1179.495
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS  (STU:A71) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ascendis Pharma AS Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines